Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

Oligodendroglial fibroblast growth factor receptor 1 gene targeting protects mice from experimental autoimmune encephalomyelitis through ERK/AKT phosphorylation.

Rajendran R, Giraldo-Velásquez M, Stadelmann C, Berghoff M.

Brain Pathol. 2017 Jan 24. doi: 10.1111/bpa.12487. [Epub ahead of print]

PMID:
28117910
2.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.

3.

CTRP-3 is permeable to the blood-brain barrier and is not regulated by glucose or lipids in vivo.

Schmid A, Berghoff M, Hochberg A, Schäffler A, Karrasch T.

Eur J Clin Invest. 2017 Mar;47(3):203-212. doi: 10.1111/eci.12709. Epub 2017 Feb 16.

PMID:
27930815
4.

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.

Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10.

5.

Factors influencing intracranial vessel densities on unenhanced computed tomography: differences between hemispheres.

Grams AE, Rehwald R, Schmittnägel C, Schmidt T, Tanislav C, Berghoff M, Krombach GA, Moritz R, Obert M, Gizewski ER, Glodny B.

Clin Imaging. 2016 Nov - Dec;40(6):1081-1085. doi: 10.1016/j.clinimag.2016.06.012. Epub 2016 Jun 25.

PMID:
27421082
6.

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.

O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas.

Neurology. 2016 Mar 8;86(10):920-30. doi: 10.1212/WNL.0000000000002441. Epub 2016 Feb 10. Erratum in: Neurology. 2016 Oct 4;87(14 ):1524.

7.

Quantification and regulation of the adipokines resistin and progranulin in human cerebrospinal fluid.

Berghoff M, Hochberg A, Schmid A, Schlegel J, Karrasch T, Kaps M, Schäffler A.

Eur J Clin Invest. 2016 Jan;46(1):15-26. doi: 10.1111/eci.12558. Epub 2015 Dec 1.

PMID:
26509463
8.

Quantification and regulation of adipsin in human cerebrospinal fluid (CSF).

Schmid A, Hochberg A, Berghoff M, Schlegel J, Karrasch T, Kaps M, Schäffler A.

Clin Endocrinol (Oxf). 2015 Jul 17. doi: 10.1111/cen.12856. [Epub ahead of print]

PMID:
26186410
9.

Compound Droplets on Fibers.

Weyer F, Ben Said M, Hötzer J, Berghoff M, Dreesen L, Nestler B, Vandewalle N.

Langmuir. 2015 Jul 21;31(28):7799-805. doi: 10.1021/acs.langmuir.5b01391. Epub 2015 Jul 8.

PMID:
26090699
10.

A Costa Rican family affected with Charcot-Marie-Tooth disease due to the myelin protein zero (MPZ) p.Thr124Met mutation shares the Belgian haplotype.

Leal A, Berghoff C, Berghoff M, Rojas-Araya M, Carolina O, Heuss D, Del Valle G, Rautenstrauss B.

Rev Biol Trop. 2014 Dec;62(4):1285-93.

PMID:
25720167
11.

MK2 and Fas receptor contribute to the severity of CNS demyelination.

Tietz SM, Hofmann R, Thomas T, Tackenberg B, Gaestel M, Berghoff M.

PLoS One. 2014 Jun 25;9(6):e100363. doi: 10.1371/journal.pone.0100363. eCollection 2014.

12.

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group.

Lancet Neurol. 2014 Mar;13(3):247-56. doi: 10.1016/S1474-4422(13)70308-9. Epub 2014 Jan 23.

PMID:
24461574
13.

Phase-field simulations at the atomic scale in comparison to molecular dynamics.

Berghoff M, Selzer M, Nestler B.

ScientificWorldJournal. 2013 Dec 19;2013:564272. doi: 10.1155/2013/564272. eCollection 2013.

14.

Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial.

Köpke S, Kern S, Ziemssen T, Berghoff M, Kleiter I, Marziniak M, Paul F, Vettorazzi E, Pöttgen J, Fischer K, Kasper J, Heesen C.

J Neurol Neurosurg Psychiatry. 2014 Apr;85(4):411-8. doi: 10.1136/jnnp-2013-306441. Epub 2013 Oct 8.

PMID:
24104856
15.

No evidence for CCVSI in relapsing-remitting multiple sclerosis patients with moderate disability.

Juenemann M, Yeniguen M, Stolz E, Berghoff M.

J Neurol. 2013 Sep;260(9):2409-10. doi: 10.1007/s00415-013-7034-8. Epub 2013 Jul 14. No abstract available.

PMID:
23852660
16.

A case of natalizumab-associated progressive multifocal leukoencephalopathy-role for advanced MRI?

Berghoff M, Dassinger B, Iwinska-Zelder J, Giraldo M, Bilgin S, Kaps M, Gizewski ER.

Clin Neuroradiol. 2014 Jun;24(2):173-6. doi: 10.1007/s00062-013-0216-z. Epub 2013 Mar 27. No abstract available.

PMID:
23532437
17.

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.

Wolinsky JS, Narayana PA, Nelson F, Datta S, O'Connor P, Confavreux C, Comi G, Kappos L, Olsson TP, Truffinet P, Wang L, Miller A, Freedman MS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group.

Mult Scler. 2013 Sep;19(10):1310-9. doi: 10.1177/1352458513475723. Epub 2013 Feb 27.

PMID:
23447359
18.

Development of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma 13 years after treatment with cladribine.

Berghoff M, Schänzer A, Hildebrandt GC, Dassinger B, Klappstein G, Kaps M, Gizewski ER, Acker T, Grams A.

Leuk Lymphoma. 2013 Jun;54(6):1340-2. doi: 10.3109/10428194.2012.740669. Epub 2012 Nov 20. No abstract available.

PMID:
23098217
19.

Description of hard-sphere crystals and crystal-fluid interfaces: a comparison between density functional approaches and a phase-field crystal model.

Oettel M, Dorosz S, Berghoff M, Nestler B, Schilling T.

Phys Rev E Stat Nonlin Soft Matter Phys. 2012 Aug;86(2 Pt 1):021404. Epub 2012 Aug 22.

PMID:
23005760
20.

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators.

N Engl J Med. 2012 Sep 20;367(12):1098-107. Erratum in: N Engl J Med. 2012 Dec 13;367(24):2362.

Supplemental Content

Loading ...
Support Center